 Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 L01.280.975.475.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- QALY
- Quality Adjusted Life Years
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in UAMS Profiles by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 3 | 3 | | 2022 | 0 | 2 | 2 | | 2020 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 6 | 6 | | 2015 | 1 | 4 | 5 | | 2014 | 1 | 1 | 2 | | 2013 | 0 | 1 | 1 | | 2012 | 1 | 3 | 4 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2001 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles over the past ten years.
-
Reynolds MR, Stein AB, Sun X, Hytopoulos E, Steinhubl SR, Cohen DJ. Cost-Effectiveness of AF Screening With 2-Week Patch Monitors: The mSToPS Study. Circ Cardiovasc Qual Outcomes. 2023 11; 16(11):e009751.
-
Borre ED, Johri M, Dubno JR, Myers ER, Emmett SD, Pavon JM, Francis HW, Ogbuoji O, Sanders Schmidler GD. Potential Clinical and Economic Outcomes of Over-the-Counter Hearing Aids in the US. JAMA Otolaryngol Head Neck Surg. 2023 07 01; 149(7):607-614.
-
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Butzner M, Chi? A, Andrews JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. J Med Econ. 2023 Jan-Dec; 26(1):488-493.
-
Borre ED, Myers ER, Dubno JR, Emmett SD, Pavon JM, Francis HW, Ogbuoji O, Sanders Schmidler GD. Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule. JAMA Health Forum. 2022 11 04; 3(11):e224065.
-
Borre ED, Dubno JR, Myers ER, Emmett SD, Pavon JM, Francis HW, Ogbuoji O, Sanders Schmidler GD. Model-Projected Cost-Effectiveness of Adult Hearing Screening in the USA. J Gen Intern Med. 2023 03; 38(4):978-985.
-
Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Clin Ther. 2020 05; 42(5):860-872.e8.
-
Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 04; 23(4):451-460.
-
Manz KC, Waters TM, Clifton HE, Kocak M, Klesges RC, Talcott GW, Krukowski RA. Cost-Effectiveness of a Weight Loss Intervention: An Adaptation of the Look AHEAD Lifestyle Intervention in the US Military. Obesity (Silver Spring). 2020 01; 28(1):89-96.
-
Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 07; 122(1):50-58.
-
Rajan PV, Qudsi RA, Wolf LL, Losina E. Cost-Effectiveness Analyses in Orthopaedic Surgery: Raising the Bar. J Bone Joint Surg Am. 2017 07 05; 99(13):e71.
-
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016 11; 44(10):1090-1101.
-
Emmett SD, Tucci DL, Bento RF, Garcia JM, Juman S, Chiossone-Kerdel JA, Liu TJ, de Mu?oz PC, Ullauri A, Letort JJ, Mansilla T, Urquijo DP, Aparicio ML, Gong W, Francis HW, Saunders JE. Moving Beyond GDP: Cost Effectiveness of Cochlear Implantation and Deaf Education in Latin America. Otol Neurotol. 2016 09; 37(8):1040-8.
-
Cressman S, Karsan A, Hogge DE, McPherson E, Bolbocean C, Regier DA, Peacock SJ. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br J Haematol. 2016 08; 174(4):526-35.
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
-
de Vlas SJ, Stolk WA, le Rutte EA, Hontelez JA, Bakker R, Blok DJ, Cai R, Houweling TA, Kulik MC, Lenk EJ, Luyendijk M, Matthijsse SM, Redekop WK, Wagenaar I, Jacobson J, Nagelkerke NJ, Richardus JH. Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004386.
-
Ferguson A, Yates C, Tilford JM. Value-based insurance designs in the treatment of mental health disorders. Am J Manag Care. 2016 Jan 01; 22(1):e38-44.
-
Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016; 19(3):243-58.
-
Payakachat N, Ali MM, Tilford JM. Can The EQ-5D Detect Meaningful Change? A Systematic Review. Pharmacoeconomics. 2015 Nov; 33(11):1137-54.
-
Tilford JM, Payakachat N, Kuhlthau KA, Pyne JM, Kovacs E, Bellando J, Williams DK, Brouwer WB, Frye RE. Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. J Autism Dev Disord. 2015 Nov; 45(11):3613-23.
-
Emmett SD, Tucci DL, Smith M, Macharia IM, Ndegwa SN, Nakku D, Mukara KB, Kaitesi MB, Ibekwe TS, Mulwafu W, Gong W, Francis HW, Saunders JE. GDP Matters: Cost Effectiveness of Cochlear Implantation and Deaf Education in Sub-Saharan Africa. Otol Neurotol. 2015 Sep; 36(8):1357-65.
-
Balakrishnan K, Bauman N, Chun RH, Darrow DH, Grimmer JF, Perkins JA, Richter GT, Shin JJ, Shivaram GM, Sidell DR, Elluru RG. Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations. Otolaryngol Head Neck Surg. 2015 May; 152(5):948-53.
-
Fortney JC, Pyne JM, Burgess JF. Population-level cost-effectiveness of implementing evidence-based practices into routine care. Health Serv Res. 2014 Dec; 49(6):1832-51.
-
Payakachat N, Tilford JM, Kuhlthau KA, van Exel NJ, Kovacs E, Bellando J, Pyne JM, Brouwer WB. Predicting health utilities for children with autism spectrum disorders. Autism Res. 2014 Dec; 7(6):649-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|